Clinical Trial Update: Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase II study of clofarabine in adults with refractory or relapsed acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clolar (Clofarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED